SAN DIEGO — New research highlights a mismatch between lung cancer screening eligibility criteria and actual lung cancer risk, which means many patients who develop lung […]

Burnout, a syndrome caused by work overload, is one of the main challenges in the medical profession. Although it is a general problem, certain professionals, such […]

The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly diagnosed, advanced, high-grade ovarian cancer (AHGOC), […]

A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those with brain metastases.  Senior author Nancy […]

BARCELONA — Adding lenvatinib and pembrolizumab to transarterial chemoembolization (TACE) led to a significant improvement in progression-free survival in patients with intermediate-stage hepatocellular carcinoma compared with […]

BARCELONA — The combination of standard FOLFOX chemotherapy with doublet immunotherapy did not improve progression-free survival compared with chemotherapy alone in patients with HER2-negative gastric or gastroesophageal […]

Adjuvant durvalumab (Imfinzi) provided no significant improvement in disease-free survival compared with placebo following resection in patients with early-stage non-small cell lung cancer (NSCLC), according to […]